Milan, Italy, 1 April 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing novel disease-modifying biologics that re-establish stem cell capabilities to treat specific autoimmune diseases, today announces the appointment of Claudia Nardini as Vice President of Research and Development to support the Company’s manufacturing and regulatory divisions. Claudia has 25 years of experience in […]
/wp-content/uploads/2019/10/logo_enthera.svg00hearten/wp-content/uploads/2019/10/logo_enthera.svghearten2021-04-01 09:00:432021-03-31 16:38:29Enthera Pharmaceuticals Appoints Claudia Nardini as Vice President of Research and Development
The Roche Venture Fund joins international investor syndicate, including co-lead investors Sofinnova Partners and AbbVie Ventures Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease Largest international VC-backed Series A financing round for a biotech in Italy to date and first ever venture investment in an Italian company […]
/wp-content/uploads/2019/10/logo_enthera.svg00hearten/wp-content/uploads/2019/10/logo_enthera.svghearten2021-01-28 09:00:522021-01-28 09:24:12Enthera Pharmaceuticals extends Series A financing, raising a total of €35 million
Milan, Italy, 3 December 2020 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.
/wp-content/uploads/2019/10/logo_enthera.svg00hearten/wp-content/uploads/2019/10/logo_enthera.svghearten2020-12-03 08:00:022020-12-03 08:44:30Enthera Pharmaceuticals appoints Kazumi Shiosaki to its Board of Directors and Lisa Olson to its Scientific Advisory Board to push forward company growth and development
Enthera Pharmaceuticals Appoints Claudia Nardini as Vice President of Research and Development
/in Press Releases /by heartenMilan, Italy, 1 April 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing novel disease-modifying biologics that re-establish stem cell capabilities to treat specific autoimmune diseases, today announces the appointment of Claudia Nardini as Vice President of Research and Development to support the Company’s manufacturing and regulatory divisions. Claudia has 25 years of experience in […]
Enthera Pharmaceuticals extends Series A financing, raising a total of €35 million
/in Press Releases /by heartenThe Roche Venture Fund joins international investor syndicate, including co-lead investors Sofinnova Partners and AbbVie Ventures Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease Largest international VC-backed Series A financing round for a biotech in Italy to date and first ever venture investment in an Italian company […]
Enthera Pharmaceuticals appoints Kazumi Shiosaki to its Board of Directors and Lisa Olson to its Scientific Advisory Board to push forward company growth and development
/in Press Releases /by heartenMilan, Italy, 3 December 2020 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.